New foam treatment could help kids with colitis avoid stronger drugs
NCT ID NCT05976802
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a steroid foam (budesonide) given rectally to children aged 5 to 17 with mild to moderate ulcerative colitis in the lower colon. The goal is to see if it can safely induce remission after 6 weeks of treatment. About 100 children will receive either a low dose, high dose, or placebo foam twice daily for 2 weeks, then once daily for 4 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- budesonide rectal foam
- What this could lead to
- If successful, this could provide a new treatment option for children with ulcerative colitis, helping them achieve remission without stronger medications.
- What could go wrong
- This is a phase 4 trial, but it's still early for this specific age group. The placebo group may also improve, and the foam may not work better than placebo. Side effects like irritation or infection are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a glass of pomegranate juice tame gut inflammation?